Skip to main content
Home

Primary Menu

  • OUR STRATEGY
    • WHAT SETS US APART
    • OUR HISTORY
    • OUR LEADERSHIP
    • FAQ
  • OUR IMPACT
    • WHAT WE SUPPORT
    • CURRENT PROJECTS
    • TIMELINE
  • GET INVOLVED
    • WAYS TO DONATE
    • BECOME A SPONSOR
    • LEGACY PLANNING
    • FUNDRAISE
    • CORPORATE PARTNERS
  • FOR SCIENTISTS
    • AWARD PROGRAMS
    • APPLICATION GUIDELINES
    • GENERATIONS OF INNOVATORS
    • SELECTION COMMITTEES
    • ACCELERATING CANCER CURES
    • FAQ
  • NEWS
  • BROADWAY TICKETS
  • burger-menu
Search
search-button-x

Donate

  • DONATE

Damon Runyon News

View New Articles By

News

New DiscoveriesNovember 28, 2016
Damon Runyon scientist awarded 2016 Vanderbilt Prize in Biomedical Science

Elaine V. Fuchs, PhD (Damon Runyon Board Member, Damon Runyon Fellow ‘77-‘79) of The Rockefeller University, New York, was announced the recipient of the 2016 Vanderbilt Prize in Biomedical Science. She is the 11th recipient of the Prize, which honors women scientists with a "stellar record" of research accomplishments who have made significant contributions to mentoring other women in science. Her innovative use of reverse genetics has helped redefine the study of skin diseases and cancer stem cells.

Read More
New DiscoveriesNovember 9, 2016
Liquid biopsy can predict lymphoma prognosis and treatment decisions

Ash Alizadeh (Damon Runyon Clinical Investigator ’14-’17) and colleagues at Stanford University School of Medicine reported that circulating tumor DNA (ctDNA) profiling by non-invasive liquid biopsy reveals distinct patterns of clonal evolution and allows accurate classification of tumor subtypes in lymphoma patients. This enables insights into the biology of how an indolent disease transitions into an aggressive and often fatal disease.

Read More
New DiscoveriesNovember 8, 2016
Former Damon Runyon Clinical Investigator elected to the National Academy of Medicine

Maura L. Gillison, MD, PhD (Damon Runyon-Lilly Clinical Investigator ‘00-‘05) of the Ohio State University Comprehensive Cancer Center, Columbus, was elected a member of the National Academy of Medicine. This is one of the country’s highest and most prestigious honors in the fields of health and medicine. She is recognized for having made fundamental contributions to demonstrating the link between the human papillomavirus virus (HPV) and head and neck cancers.

Read More
New DiscoveriesOctober 4, 2016
2016 High-Risk, High-Reward Research Awards granted

The NIH announced the 2016 recipients of awards within its High-Risk, High-Reward Research program. These awards are designed to support scientists proposing highly innovative approaches to major contemporary challenges in biomedical research. Of 88 total awards this year, six were granted to Damon Runyon Scientists. 

2016 Pioneer Award

Christine Mayr, MD, PhD (Damon Runyon Innovator '13-'15), Memorial Sloan Kettering Cancer Center, New York

2016 NIH New Innovator Award

Read More
New DiscoveriesSeptember 21, 2016
2016 MacArthur Fellows selected

Dianne K. Newman, PhD (Damon Runyon Fellow ’88-‘89) of California Institute of Technology, Pasadena, was named one of 23 MacArthur Fellows for 2016. She is recognized for her innovative research investigating the role that bacteria have played in shaping the Earth and continue to play in modern biomedical contexts. The MacArthur Fellows Program awards five-year, unrestricted fellowships to individuals across all ages and fields who show exceptional merit and promise of continued creative work. 

Read More
New DiscoveriesSeptember 13, 2016
2016 Lasker Awards

Congratulations to the six researchers named recipients of The Lasker Awards, among the most respected prizes in medicine. William G. Kaelin, Jr., MD (Damon Runyon Board Member, Chair of the Physician-Scientist Training Award Committee) of Dana-Farber Cancer Institute, Boston, received the Albert Lasker Basic Medical Research Award for his work to understand the pathway cells use to sense and adapt to changes in oxygen levels which led to the development of potential drugs for heart attack, stroke, and kidney cancer. Bruce M.

Read More
New DiscoveriesSeptember 9, 2016
Possible new therapeutic target for cancer identified

Arvin C. Dar, PhD (Damon Runyon-Rachleff Innovator '14-'16) at the Icahn School of Medicine at Mount Sinai, reported that a “scaffolding protein” called the kinase suppressor of Ras (KSR) could be targeted as a way to disrupt signaling from mutant Ras protein. About 25 percent of human cancers have mutations in the Ras protein that disrupt growth signals and cause tumor development.  The researchers tested over 170 compounds and discovered that one could effectively slow cancer growth.

Read More
New DiscoveriesSeptember 7, 2016
Umbilical cord blood transplant improves survival for high-risk leukemia patients

Colleen Delaney, MD, MSc (Damon Runyon Clinical Investigator ’07-’12) and colleagues at the Fred Hutchinson Cancer Research Center, Seattle, developed a method for using umbilical cord stem cells as a source of donor material for transplant. This is important because the majority of patients in need of a hematopoietic-cell transplant do not have a matched related donor. The advance is particularly valuable for minorities and people of mixed-race background.

Read More
New DiscoveriesJuly 20, 2016
New understanding of mechanism underlying pediatric rhabdomyosarcoma

Amit J. Sabnis, MD (Damon Runyon-Sohn Pediatric Cancer Fellow ’13-’17), of the University of California, San Francisco, and colleagues, demonstrated that cancer cells co-opt a cellular “chaperone” protein called HSP70 (heat-shock protein 70) to promote their growth. By blocking that pathway, the scientists were able to kill cells derived from patients with rhabdomyosarcoma (RMS), a rare muscle-tissue cancer that affects children.

Read More
New DiscoveriesJuly 14, 2016
Immunotherapy benefits relapsed post-transplant patients

Pavan Bachireddy, MD (Damon Runyon Physician-Scientist ’15-’19), Catherine J. Wu, MD (Damon Runyon-Lilly Clinical Investigator ’07-’12), and colleagues at the Dana-Farber Cancer Institute, Boston, reported that a new treatment approach, using repeated doses of the immunotherapy drug ipilimumab, may be able to restore a complete remission for some patients with advanced blood cancers that relapse after stem-cell transplant.

Read More

Pagination

  • First page « First
  • Previous page ‹ Previous
  • …
  • Page 21
  • Page 22
  • Page 23
  • Page 24
  • Page 25
  • Page 26
  • Page 27
  • Page 28
  • Page 29
  • …
  • Next page Next ›
  • Last page Last »

ABOUT

Annual Reports + Report Cards
Financial Overview
Our Team

CONNECT

1.877.7CANCER
info@damonrunyon.org
One Exchange Plaza
55 Broadway, Suite 302
New York, NY 10006

Damon Runyon Cancer Research Foundation on Facebook Damon Runyon Cancer Research Foundation on LinkedIn Damon Runyon Cancer Research Foundation on BlueSky Damon Runyon Cancer Research Foundation on Instagram Damon Runyon Cancer Research Foundation on Youtube

    

© COPYRIGHT DAMON RUNYON. ALL RIGHTS RESERVED

PRIVACY POLICY